FDA Oncology Announcements

Alkylating agent × Genitourinary × Clear all

3 Announcements

FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer

Trial: ENVISION
Drug: Zusduri (mitomycin intravesical solution) · Alkylating agent
Condition: Genitourinary

FDA approves mitomycin for low-grade upper tract urothelial cancer

Trial: Olympus
Drug: JELMYTO (mitomycin) · Alkylating agent
Condition: Genitourinary

FDA approves mitomycin for low-grade upper tract urothelial cancer

Trial: Olympus
Drug: JELMYTO (mitomycin) · Alkylating agent
Condition: Genitourinary